Lebrikizumab

From WikiMD.org
Jump to navigation Jump to search

Lebrikizumab

Lebrikizumab (pronounced leb-ri-ki-zu-mab) is a monoclonal antibody designed for the treatment of asthma and other inflammatory diseases. It is currently under development by Roche and Genentech.

Etymology

The name "Lebrikizumab" is derived from the International Nonproprietary Names (INN), where "zu" refers to humanized antibody, "mab" refers to monoclonal antibody, and "lebriki" is a unique stem.

Mechanism of Action

Lebrikizumab works by targeting and neutralizing interleukin-13 (IL-13), a cytokine involved in inflammatory responses. By blocking IL-13, lebrikizumab can reduce inflammation and improve symptoms in diseases where IL-13 plays a key role.

Clinical Trials

Lebrikizumab has been tested in several clinical trials for its efficacy and safety in treating asthma and atopic dermatitis. The results have shown promise, but further research is needed to fully understand its potential benefits and risks.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski